NovaBridge Biosciences in brief
NovaBridge Biosciences is a listed company in the Biotechnology industry, based in China. Its last known market value was $177 M (January 2024); there is no current figure. It employs about 228 people. Its shares trade under the symbol NBP (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About NovaBridge Biosciences
I-Mab is a Clinical Stage Biopharmaceutical company. It is committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company annual revenue is 114.5 million USD. The headquarters is in China.
NovaBridge Biosciences timeline
- 2020
- 🔔· approximateInitial public offering on Nasdaq
Events of NovaBridge Biosciences from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in China: #786 (Jan 2021) · #988 (Jan 2022) · #4,528 (Dec 2022) · #4,813 (Jul 2023) · #4,978 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -20.0%
- Liabilities / assets
- 11.4%
- Revenue growth
- -95.4%
- R&D / revenue
- 3404.8%
- Profit per employee
- $-203 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-94M | $-46M | — |
| Dec 2024 | — | — | $-51M | $-22M | — |
| Dec 2023 | $1M | — | $-72M | $-208M | -32973.0% |
| Dec 2022 | — | — | $-53M | $-371M | — |
| Dec 2021 | $14M | -94.2% | — | $-366M | -2649.3% |
| Dec 2020 | $236M | +5385.4% | — | $72M | 30.5% |
| Dec 2019 | $4M | +152.0% | — | $-209M | -4839.0% |
| Dec 2017 | $2M | — | — | $-44M | -2580.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-21M | $0M | $-21M | $-0.21 | — |
| Dec 2024 | $-53M | $0M | $-53M | $-0.12 | — |
| Dec 2023 | $-184M | $0M | $-184M | $-1.09 | — |
| Dec 2022 | $-160M | $2M | $-162M | $-1.96 | — |
| Dec 2021 | $-153M | $5M | $-157M | $-2.09 | — |
| Dec 2020 | $66M | $1M | $65M | $0.46 | — |
| Dec 2019 | $-125M | $2M | $-126M | $-28.90 | — |
| Dec 2017 | $-37M | $3M | $-40M | $-7.68 | — |
Annual results
- Revenue
- —
- Operating income
- $-94 M
- Net income
- $-46 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $261 M
- Total liabilities
- $30 M
- Total equity
- $231 M
As of December-2025
Top 48 institutional investors in NovaBridge Biosciences#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Hhlr Advisors, LTD. | 5,980,568 | 0 (0.00%) | $8 M | Nov 16, 2026 |
| 2 | Morgan Stanley | 3,471,552 | -181,676 (-4.97%) | $5 M | Nov 13, 2026 |
| 3 | AIHC Capital Management Ltd | 2,878,033 | 0 (0.00%) | $4 M | Nov 16, 2026 |
| 4 | Citadel Advisors LLC | 1,381,516 | +758,685 (+121.81%) | $2 M | Nov 16, 2026 |
| 5 | Candriam S.C.A. | 1,132,563 | 0 (0.00%) | $2 M | Nov 3, 2026 |
| 6 | Adage Capital Partners GP, L.L.C. | 1,000,000 | 0 (0.00%) | $1 M | Nov 16, 2026 |
| 7 | Two Sigma Investments, LP | 874,250 | +22,902 (+2.69%) | $1 M | Nov 16, 2026 |
| 8 | BlackRock, Inc. | 749,282 | +63,074 (+9.19%) | $1 M | Nov 13, 2026 |
| 9 | Marshall Wace, LLP | 727,345 | -504,601 (-40.96%) | $1 M | Nov 13, 2026 |
| 10 | UBS Group AG | 689,762 | +387,982 (+128.56%) | $1 M | Nov 10, 2026 |
| 11 | Exome Asset Management LLC | 576,960 | 0 (0.00%) | $1 M | Nov 16, 2026 |
| 12 | Diadema Partners LP | 500,000 | New | $1 M | Nov 16, 2026 |
| 13 | Renaissance Technologies LLC | 485,191 | -273,035 (-36.01%) | $1 M | Nov 12, 2026 |
| 14 | Woodline Partners LP | 350,000 | 0 (0.00%) | $0 M | Nov 16, 2026 |
| 15 | Fiera Capital Corp | 315,681 | 0 (0.00%) | $0 M | Nov 6, 2026 |
| 16 | State Street Corp | 312,640 | -47,736 (-13.25%) | $0 M | Nov 12, 2026 |
| 17 | XTX Topco Ltd | 159,492 | New | $0 M | Nov 16, 2026 |
| 18 | Alps Advisors Inc | 150,167 | +33,071 (+28.24%) | $0 M | Nov 3, 2026 |
| 19 | Jane Street Group, LLC | 145,666 | +127,323 (+694.12%) | $0 M | Nov 12, 2026 |
| 20 | Persistent Asset Partners Ltd | 126,943 | New | $0 M | Nov 13, 2026 |
| 21 | Goldman Sachs Group Inc | 124,643 | -36,678 (-22.74%) | $0 M | Nov 16, 2026 |
| 22 | Quadrature Capital Ltd | 109,026 | New | $0 M | Nov 13, 2026 |
| 23 | Acadian Asset Management LLC | 98,344 | New | $0 M | Nov 9, 2026 |
| 24 | Invesco Ltd. | 73,731 | +10,846 (+17.25%) | $0 M | Nov 12, 2026 |
| 25 | HRT Financial LP | 59,010 | New | $0 M | Nov 13, 2026 |
Show all 48: investors 26 to 48
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 26 | Geode Capital Management, LLC | 44,124 | -24,725 (-35.91%) | $0 M | Nov 6, 2026 |
| 27 | Dimensional Fund Advisors LP | 39,009 | -77,332 (-66.47%) | $0 M | Nov 4, 2026 |
| 28 | Tower Research Capital LLC (TRC) | 29,965 | +25,639 (+592.67%) | $0 M | Nov 16, 2026 |
| 29 | Squarepoint Ops LLC | 23,551 | -2,917 (-11.02%) | $0 M | Nov 9, 2026 |
| 30 | BNP Paribas Financial Markets | 20,733 | -8,103 (-28.10%) | $0 M | Nov 12, 2026 |
| 31 | Nations Financial Group Inc, /ia/ /adv | 20,575 | New | $0 M | Nov 5, 2026 |
| 32 | China Universal Asset Management Co., Ltd. | 20,480 | +2,616 (+14.64%) | $0 M | Oct 28, 2026 |
| 33 | Jpmorgan Chase & Co | 19,428 | -62,128 (-76.18%) | $0 M | Nov 12, 2026 |
| 34 | Group One Trading LLC | 15,553 | +15,410 (+10776.22%) | $0 M | Nov 10, 2026 |
| 35 | Susquehanna International Group, LLP | 14,839 | -13,700 (-48.00%) | $0 M | Nov 16, 2026 |
| 36 | Bronte Capital Management Pty Ltd. | 11,192 | 0 (0.00%) | $0 M | Nov 12, 2026 |
| 37 | Barclays PLC | 10,198 | -268,821 (-96.35%) | $0 M | Nov 6, 2026 |
| 38 | Freestone Capital Holdings, LLC | 10,000 | 0 (0.00%) | $0 M | Nov 9, 2026 |
| 39 | Police & Firemen's Retirement System of New Jersey | 8,521 | New | $0 M | Nov 9, 2026 |
| 40 | Mirae Asset Global Investments Co., Ltd. | 5,736 | +716 (+14.26%) | $0 M | Oct 29, 2026 |
| 41 | Citigroup Inc | 3,033 | +343 (+12.75%) | $0 M | Nov 4, 2026 |
| 42 | GF Fund Management Co. LTD. | 2,588 | +211 (+8.88%) | $0 M | Oct 26, 2026 |
| 43 | PNC Financial Services Group, Inc. | 2,000 | 0 (0.00%) | $0 M | Nov 6, 2026 |
| 44 | SBI Securities Co., Ltd. | 1,070 | +995 (+1326.67%) | $0 M | Oct 22, 2026 |
| 45 | Caitong International Asset Management Co., Ltd | 177 | -30,104 (-99.42%) | $0 M | Oct 29, 2026 |
| 46 | Strategic Financial Concepts, LLC | 75 | New | $0 M | Nov 16, 2026 |
| 47 | Rhumbline Advisers | 33 | 0 (0.00%) | $0 M | Nov 10, 2026 |
| 48 | Eurizon Capital SGR S.p.A. | 1 | 0 (0.00%) | $0 M | Nov 6, 2026 |
Mutual funds holding NovaBridge Biosciences#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 591,381 | $1 M | — | 0.01% | +9.6% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR Portfolio Emerging Markets ETFSSGA Funds Management, Inc. | 297,847 | $1 M | — | <0.01% | −1.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 68,849 | $0 M | — | <0.01% | +21% | May 31, 2026 |
| 🇺🇸 State Street SPDR S&P Emerging Markets Small Cap ETFSSGA Funds Management, Inc. | 48,319 | $0 M | — | 0.01% | −6.8% | Jun 30, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 26,330 | $0 M | — | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Core Equity 2 PortfolioDimensional Fund Advisors LP | 20,035 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P China ETFSSGA Funds Management, Inc. | 14,210 | $0 M | — | <0.01% | −3.8% | Jun 30, 2026 |
| 🇺🇸 Emerging Markets Social Core Equity PortfolioDimensional Fund Advisors LP | 15,130 | $0 M | — | <0.01% | −35% | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 9,306 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 5,100 | $0 M | — | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at NovaBridge Biosciences#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mark Arnold HaglerChief Commercial Officer | Buy | +184,000 | $0.381 | $70 K | 460,000 | Form 4 |
| filed | Mark Arnold HaglerChief Commercial Officer | Buy | +46,000 | $0.343 | $16 K | 276,000 | Form 4 |
| filed | Ian Ying WooDirector | Option exercise | +13,271 | — | — | 13,271 | Form 4 |
| filed | Phillip Andrew DennisChief Medical Officer | Sell | -8,209 | $0.710 | $6 K | 173,427 | Form 4 |
| filed | Phillip Andrew DennisChief Medical Officer | Option exercise | +23,695 | — | — | 181,636 | Form 4 |
| filed | Sean Wuxiong CaoChief Bus. Development Officer | Sell | -107,978 | $0.740 | $80 K | 266,467 | Form 4 |
| filed | Sean Wuxiong CaoChief Bus. Development Officer | Option exercise | +235,136 | — | — | 270,209 | Form 4 |
| filed | Sean Wuxiong CaoChief Bus. Development Officer | Option exercise | +104,236 | — | — | 374,445 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: NovaBridge Biosciences#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-10-16 20:01 UTC, code T3, resumed 20:25 UTC
Fails to deliver
- : 44,124 shares at $1.21
- : 26,125 shares at $1.33
- : 100 shares at $1.40
- : 100 shares at $1.36
- : 98 shares at $1.36
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
NovaBridge Biosciences scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.21 vs -0.12Diluted EPS -0.21 in fiscal 2025 against -0.12 the year before (report's currency).
- ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against $72 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-21.4%-21.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities8.1×Current ratio 8.09 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year18.0%Diluted shares up 18.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
NovaBridge Biosciences: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 · USD | FY 2024to Dec 31, 2024 · USD | FY 2023to Dec 31, 2023 · USD | FY 2022to Dec 31, 2022 · USD | FY 2021to Dec 31, 2021 · CNY | FY 2020to Dec 31, 2020 · CNY | FY 2019to Dec 31, 2019 · CNY | FY 2018to Dec 31, 2018 · CNY | FY 2017to Dec 31, 2017 · CNY |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 0.6r3.9—100% | −1.6r−32—— | 88−94.3%100% | 1,543+5042%100% | 30−44.2%100% | 54+365%100% | 12—100% | |
| Cost of revenue | — | — | — | 3.9—— | 46—52.7% | 0—0.0% | 0—0.0% | — | — | |
| Research and development | 63+189%— | 22+1.5%— | 21r114−4.9%3394% | 23r131—— | 1,213+23.2%1378% | 985+17.2%63.8% | 840+97.3%2801% | 426+59.5%792% | 267—2311% | |
| General and administrative | 31+5.8%— | 30+5.3%— | 28r64−2.8%4456% | 29r118—— | 900+124%1022% | 402−38.5%26.1% | 655+886%2182% | 66+161%123% | 25—220% | |
| Operating expenses | 94+83.3%— | 51−29.2%— | 73+41.0%11495% | 52—— | — | — | — | — | — | |
| Operating income | −94—— | −51—— | −72—−11395% | −53—— | — | — | — | — | — | |
| Interest and finance income | 7.6+1.7%— | 7.5−19.5%— | 9.3r7.3+87.6%1471% | 5.0r3.9—— | 21−11.9%24.2% | 24−20.7%1.6% | 31+565%102% | 4.6+436%8.5% | 0.9—7.4% | |
| Interest expense and finance costs | — | — | 0.1+10100%16.1% | 0.0—— | 0−100%0.0% | 1.0−68.0%0.1% | 3.0−74.4%10.0% | 12+107%21.7% | 5.6—48.8% | |
| Share of profit of associates | — | −1.0—— | −11r−11—−1804% | −65r−63—— | −368—−418% | −109—−7.0% | 0—0.0% | — | — | |
| Other non-operating income (expense) | −1.7—— | −4.7—— | −8.1r−5.4—−1280% | −28r−18—— | 83−79.9%94.5% | 413—26.8% | −20—−67.3% | −17−1199%−31.2% | 1.5—13.2% | |
| Income before tax | −88—— | −50—— | −82r−206—−13009% | −141r−363—— | −2,335−583%−2652% | 483—31.3% | −1,452—−4840% | −401—−746% | −298—−2581% | |
| Income tax | 0—— | 0—— | 0−100%0.0% | 0.1r0.1—— | −3.2−126%−3.6% | 12—0.8% | 0−100%0.0% | 1.7—3.2% | — | |
| Income from continuing operations | −46—— | −50—— | −82r−197—−13009% | −141r−286—— | −2,071−1431%−2353% | 156—10.1% | −1,465—−4883% | −439—−816% | −281—−2431% | |
| Income from discontinued operations | 0−100%— | 27—— | −126—−19859% | −230—— | — | — | — | — | — | |
| Net income including minority interests | −88—— | −22—— | −208—−32869% | — | — | — | — | — | — | |
| Minority interests' share of net income | −42—— | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −46—— | −22—— | −208r−206—−32869% | −371r−364—— | −2,332−595%−2649% | 471—30.5% | −1,452—−4840% | −403—−749% | −298—−2581% | |
| Earnings per share, basic | -0.21—— | -0.12—— | -1.09r-1.08—— | -1.96r-1.92—— | -13.35−480%— | 3.51—— | -201.19—— | -61.70—— | -51.93—— | |
| Earnings per share, diluted | -0.21—— | -0.12—— | -1.09r-1.08—— | -1.96r-1.92—— | -13.35−545%— | 3.00—— | -201.19—— | -61.70—— | -51.93—— | |
| Shares, weighted average (basic) | 220+18.0%— | 187−2.5%— | 191+0.9%— | 190—— | 175+30.2%— | 134+1718%— | 7.4+13.1%— | 6.5—— | — | |
| Shares, weighted average (diluted) | 220+18.0%— | 187−2.5%— | 191+0.9%— | 190—— | 175+11.1%— | 157+2030%— | 7.4+13.1%— | 6.5+13.7%— | 5.7—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 211+209%80.8% | 68−76.6%32.1% | 292r302−15.0%79.0% | 343r466—58.1% | 3,524−26.0%62.9% | 4,759+318%75.1% | 1,137−28.4%65.5% | 1,588+285%66.8% | 413—— | |
| Short-term investments | 0.2−99.8%0.1% | 105+420%49.4% | 20r20−40.8%5.5% | 34—5.8% | 753+2289%13.4% | 32−1.5%0.5% | 32—1.8% | — | — | |
| Receivables | — | — | — | 0—0.0% | 33−74.7%0.6% | 130—2.1% | — | — | — | |
| Inventory | — | — | — | 0—0.0% | 27—0.5% | 0—0.0% | — | — | — | |
| Other current assets | 6.7+103%2.6% | 3.3+31.6%1.5% | 2.5r7.3−78.5%0.7% | 12—2.0% | 191−2.4%3.4% | 195+43.7%3.1% | 136+52.9%7.8% | 89—3.7% | — | |
| Current assets | 218+23.1%83.5% | 177−46.4%83.1% | 330r329−37.3%89.4% | 526—89.0% | 4,782−10.5%85.4% | 5,344+293%84.4% | 1,361−33.2%78.3% | 2,037—85.7% | — | |
| Property, plant and equipment | 0.1−30.3%0.1% | 0.2−88.7%0.1% | 1.8r5.1−79.9%0.5% | 8.8—1.5% | 46+80.9%0.8% | 25−16.0%0.4% | 30+8.7%1.7% | 28—1.2% | — | |
| Right-of-use (leased) assets | 2.8−21.9%1.1% | 3.6−4.8%1.7% | 3.8r6.5−58.7%1.0% | 9.2—1.5% | 113+652%2.0% | 15−8.7%0.2% | 16—0.9% | — | — | |
| Goodwill | — | — | — | 24—4.0% | 1630.0%2.9% | 1630.0%2.6% | 1630.0%9.4% | 163—6.8% | — | |
| Other intangible assets | — | — | 17−3.5%4.5% | 17—2.9% | 120−0.6%2.1% | 120−19.1%1.9% | 1490.0%8.6% | 149—6.3% | — | |
| Investments in associates | — | — | 1.7−61.9%0.5% | 4.5—0.8% | 352−47.0%6.3% | 665—10.5% | — | — | — | |
| Total assets | 261+22.5%100% | 213−42.4%100% | 369r368−37.5%100% | 591—100% | 5,601−11.6%100% | 6,334+265%100% | 1,738−26.9%100% | 2,376—100% | — | |
| Accounts payable | 17+123%6.5% | 7.5r7.6−4.0%3.5% | 7.8r50−92.3%2.1% | 102—17.3% | 593+5.8%10.6% | 561+105%8.9% | 274+304%15.7% | 68—2.8% | — | |
| Current liabilities | 27+218%10.3% | 8.5−85.5%4.0% | 58r58−47.1%15.8% | 110—18.6% | 624+8.3%11.1% | 576−2.1%9.1% | 588+70.0%33.9% | 346—14.6% | — | |
| Lease liabilities (non-current) | 2.2−29.0%0.8% | 3.1−6.0%1.4% | 3.3r3.3−29.9%0.9% | 4.7—0.8% | 82+1376%1.5% | 5.5−26.0%0.1% | 7.5—0.4% | — | — | |
| Total liabilities | 30+157%11.4% | 12−90.9%5.4% | 126r126−25.1%34.2% | 169—28.6% | 1,042+47.4%18.6% | 707+5.8%11.2% | 668+60.7%38.4% | 416—17.5% | — | |
| Retained earnings | −1,332—−511% | −1,286—−605% | −1,264r−1,173—−343% | −995—−168% | −4,355—−77.7% | −2,023—−31.9% | −2,494—−144% | −1,014—−42.7% | — | |
| Shareholders' equity | 231+14.8%88.6% | 201−17.1%94.6% | 243r242−41.9%65.8% | 418r422—70.7% | 4,560−19.0%81.4% | 5,627—88.8% | −2,035—−117% | −955—−40.2% | −300—— | |
| Minority interests | — | — | — | — | — | — | — | — | 306—— | |
| Total liabilities and equity | 261+22.5%100% | 213−42.4%100% | 369r368−37.5%100% | 591—100% | 5,601−11.6%100% | 6,334+265%100% | 1,738−26.9%100% | 2,376—100% | — | |
| Shares outstanding | 265+41.6%— | 187+1.0%— | 186−2.8%— | 191—— | 184+11.5%— | 165+1871%— | 8.40.0%— | 8.4—— | — | |
| Cash-flow statement | ||||||||||
| Depreciation and amortization | — | 0.3−40.0%— | 0.5r3.4+150%79.1% | 0.2r3.7—— | 14+8.7%15.7% | 13+29.6%0.8% | 9.8+46.3%32.7% | 6.7+319%12.5% | 1.6—13.8% | |
| Share-based compensation | 6.0—— | −1.9−119%— | 10r27−22.1%1620% | 13r52—— | 609+23.3%691% | 493+34.5%32.0% | 367+10323%1223% | 3.5−50.0%6.5% | 7.0—60.9% | |
| Cash from operating activities | −21—— | −53—— | −184—−29082% | −160—— | −973−324%−1105% | 434—28.1% | −868—−2893% | −281—−522% | −252—−2182% | |
| Capital expenditure | −0.0—— | −0.0—— | −0.2r−1.6—−25.9% | −2.1r−6.6—— | −30—−34.0% | −8.0—−0.5% | −12—−40.8% | −14—−26.8% | −20—−176% | |
| Cash from investing activities | 105—— | −136−1042%— | 14−78.3%2285% | 66—— | −727—−826% | −202−195%−13.1% | 212+2136%708% | 9.5—17.7% | −158—−1364% | |
| Cash from financing activities | 58—— | −0.3−131%— | 1.1−82.6%169% | 6.1—— | 594−82.7%675% | 3,440+2153%223% | 153−89.7%509% | 1,480+95.1%2751% | 759—6564% | |
| Exchange-rate effect on cash | — | — | — | — | −129—−146% | −107−803%−6.9% | 15−74.6%50.5% | 60—111% | −0.1—−1.1% | |
| Change in cash | 142—— | −242—— | −165r−156—−26061% | −77r−31—— | −1,235−135%−1403% | 3,565—231% | −488−138%−1625% | 1,268+264%2358% | 349—3017% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| NovaBridge Biosciences🇨🇳 | $177 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2020
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at NovaBridge Biosciences? Verify and update this profile — free
Show NovaBridge Biosciences's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.